Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million
Combined company will be focused on advancing Enliven’s clinical-stage pipeline of precision oncology programs Shares…
Year: 2023
Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates
– Initiated enrollment in Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine…
Generation Bio Outlines 2023 Strategic Priorities and Reports Fourth Quarter and Full Year 2022 Financial Results
— Company expects to announce data for Factor VIII expression in non-human primates in 2023…
ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials
FREMONT, CA, Feb. 23, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:…
Tonix Pharmaceuticals Announces New Board Member, R. Newcomb Stillwell
CHATHAM, N.J., Feb. 23, 2023 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix…
Codexis Reports Fourth Quarter and Fiscal Year 2022 Financial Results
Biotherapeutics Application of CodeEvolver® Validated by Recent Data Supporting the Potential for Three Upcoming Investigational…
Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
Advanced RLY-4008: Reported interim data with 88% overall response rate at pivotal dose and 63%…
Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
Initiated ReSPECT-GBM Phase 2 and ReSPECT- LM Phase 1 trials for CNS cancers Awarded $17.6…
Codexis and Nestlé Health Science Announce Interim Results from Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency
Interim Data from Phase 1 Proof-of-Concept Arm Indicates CDX-7108 Improves Lipid Absorption REDWOOD CITY, Calif.,…
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
– Transformational year ahead with critical Phase 2 readouts expected for programs in hepatitis B,…
Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended December 31, 2022
LOS ANGELES, Feb. 23, 2023 (GLOBE NEWSWIRE) — (NASDAQ: ENOB) — On February 16, 2023, Enochian…
Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results
– Phase 1 data for ziftomenib highlighted by 30% CR rate among 20 patients with…
SELLAS Life Sciences Announces Proposed Underwritten Public Offering
NEW YORK, Feb. 23, 2023 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (Nasdaq: SLS)…
Galapagos announces full year 2022 results and outlook for 2023
Key 2022 and post–period events Dr. Paul Stoffelsi appointed as Chief Executive Officer and Chairman…
ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors
Data to be Presented in Five Poster Presentations at the 2023 American Academy of Allergy,…
Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
Recently received U.S. FDA accelerated approval of FILSPARI™ (sparsentan), the first and only non-immunosuppressive therapy…
Collegium Reports Fourth Quarter and Full-Year 2022 Financial Results
– Generated Record Quarterly and Full-Year Net Revenue of $129.6 and $463.9 Million – …
Solarvest BioEnergy’s Non-Brokered Private Placement Receives Final Exchange Acceptance
Vancouver, British Columbia–(Newsfile Corp. – February 23, 2023) – Solarvest BioEnergy Inc. (TSXV: SVS) (“Solarvest”, or the…
Alliant Energy Announces 2022 Results
GAAP earnings per share were $2.73 in 2022 compared to $2.63 in 2021 Adjusted earnings…
MoneyLion to Participate in the KBW Fintech & Payments Conference and the Wolfe Research FinTech Forum
NEW YORK–(BUSINESS WIRE)–MoneyLion Inc. (“MoneyLion”) (NYSE:ML), the one-stop destination for financial content, products and advice,…